

The agenda is subject to change as priorities dictate.

In the event an individual cannot attend, written comments may be submitted. Any written comments received will be provided at the meeting and should be submitted to the contact person below well in advance of the meeting.

Contact Person for More Information: Theodore Katz, Executive Secretary, NIOSH, CDC, 1600 Clifton Road, Mailstop E-20, Atlanta, Georgia 30333, Telephone (513) 533-6800, Toll Free 1 (800) CDC-INFO, e-mail ocas@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: January 7, 2009.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E9-524 Filed 1-12-09; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Child Care Quarterly Case Record Report—ACF-801.

OMB No.: 0970-0167.

Description: Section 658K of the Child Care and Development Block Grant Act of 1990 (Pub. L. 101-508, 42 U.S.C. 9858) requires that States and Territories submit monthly case-level data on the children and families receiving direct services under the Child Care and Development Fund. The implementing regulations for the statutorily required reporting are at 45 CFR 98.70. Case-level reports, submitted quarterly or monthly (at grantee option), include monthly sample or full population case-level data. The data elements to be included in these reports

are represented in the ACF-801. ACF uses disaggregate data to determine program and participant characteristics as well as costs and levels of child care services provided. This provides ACF with the information necessary to make reports to Congress, address national child care needs, offer technical assistance to grantees, meet performance measures, and conduct research. Consistent with the statute and regulations, ACF requests extension of the ACF-801. With this extension, ACF is proposing several changes and clarifications to the reporting requirements and instructions.

Respondents: States, the District of Columbia, and Territories including Puerto Rico, Guam, the Virgin Islands, American Samoa, and the Northern Mariana Islands.

ANNUAL BURDEN ESTIMATES

| Instrument | Number of re-spond-ents | Number of re-sponses per re-spondent | Average burden hours per response | Total bur-den hours |
|---------------|-------------------------|--------------------------------------|-----------------------------------|---------------------|
| ACF-801 | 56 | 4 | 20 | 4,480 |

Estimated Total Annual Burden Hours: 4,480

Additional Information: Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. E-mail address: infocollection@acf.hhs.gov.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Fax: 202-395-6974, Attn: Desk Officer for the Administration for Children and Families.

Dated: January 8, 2009.

Janean Chambers,

Reports Clearance Officer.

[FR Doc. E9-447 Filed 1-12-09; 8:45 am]

BILLING CODE 4184-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2008-N-0038]

Advisory Committees; Tentative Schedule of Meetings for 2009

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory committees for 2009. During 1991, at the request of the Commissioner of Food and Drugs (the Commissioner), the Institute of Medicine (the IOM) conducted a study of the use of FDA's advisory committees. In its final report, one of the IOM's recommendations was for the agency to publish an annual

tentative schedule of its meetings in the **Federal Register**. This publication implements the IOM's recommendation.

FOR FURTHER INFORMATION CONTACT: Theresa L. Green, Advisory Committee Oversight and Management Staff (HF-4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1220.

SUPPLEMENTARY INFORMATION: The IOM, at the request of the Commissioner, undertook a study of the use of the FDA's advisory committees. In its final report in 1992, one of the IOM's recommendations was for FDA to adopt a policy of publishing an advance yearly schedule of its upcoming public advisory committee meetings in the **Federal Register**; FDA has implemented this recommendation. The annual publication of tentatively scheduled advisory committee meetings will provide both advisory committee members and the public with the opportunity, in advance, to schedule attendance at FDA's upcoming advisory committee meetings. Because the schedule is tentative, amendments to this notice will not be published in the **Federal Register**. However, changes to the schedule will be posted on the FDA

advisory committees' Internet site located at <http://www.fda.gov/oc/advisory/default.htm>. FDA will continue to publish a **Federal Register** notice 15 days in advance of each

upcoming advisory committee meeting, to announce the meeting (21 CFR 14.20). The following list announces FDA's tentatively scheduled advisory committee meetings for 2009. You may

also obtain up-to-date information by calling the Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area).

| Committee Name | Tentative Date of Meeting(s) | Advisory Committee 10-Digit Information Line Code |
|--|--|---|
| OFFICE OF THE COMMISSIONER | | |
| Pediatric Advisory Committee | March 23–24, June 22–23, September 21–22, December 7–8 | 8732310001 |
| Risk Communication Advisory Committee | February 26–27, April 30–May 1, August 13–14, November 12–13 | 8732112560 |
| Science Board to the Food and Drug Administration | February 24, May 18, August 17, November 16 | 3014512603 |
| CENTER FOR BIOLOGICS EVALUATION AND RESEARCH | | |
| Allergenic Products Advisory Committee | March 5, October 22 | 3014512388 |
| Blood Products Advisory Committee | January 9, April 1, July 20–21, November 16–17 | 3014519516 |
| Cellular, Tissue and Gene Therapies Advisory Committee | May 14–15, November 5–6 | 3014512389 |
| Transmissible Spongiform Encephalopathies Advisory Committee | To be announced | 3014512392 |
| Vaccines and Related Biological Products Advisory Committee | February 18–19, May 20–21, September 23–24, November 18–19 | 3014512391 |
| CENTER FOR DRUG EVALUATION AND RESEARCH | | |
| Anesthetic and Life Support Drugs Advisory Committee | January 29–30, April dates to be announced | 3014512529 |
| Anti-Infective Drugs Advisory Committee | To be announced | 3014512530 |
| Antiviral Drugs Advisory Committee | To be announced | 3014512531 |
| Arthritis Advisory Committee | March 5, June 16–17, October 27–28 | 3014512532 |
| Cardiovascular and Renal Drugs Advisory Committee | February 3, March 18–19, July 28–29, December 7–8 | 3014512533 |
| Dermatologic and Ophthalmic Drugs Advisory Committee | To be announced | 3014512534 |
| Drug Safety and Risk Management Advisory Committee | January 30, April dates to be announced | 3014512535 |
| Endocrinologic and Metabolic Drugs Advisory Committee | April 2–3 | 3014512536 |
| Gastrointestinal Drugs Advisory Committee | February 17 | 3014512538 |
| Nonprescription Drugs Advisory Committee | April dates to be announced | 3014512541 |
| Oncologic Drugs Advisory Committee | February 25, March 24–25, May dates to be announced, July 14–15, September 15–16, December 16–17 | 3014512542 |
| Peripheral and Central Nervous System Drugs Advisory Committee | January 7–8 | 3014512543 |
| Pharmaceutical Science and Clinical Pharmacology, Advisory Committee for | March dates to be announced | 3014512539 |
| Psychopharmacologic Drugs Advisory Committee | March 26 | 3014512544 |
| Pulmonary-Allergy Drugs Advisory Committee | February 4 | 3014512545 |
| Reproductive Health Drugs, Advisory Committee for | May and August dates to be announced | 3014512537 |
| CENTER FOR DEVICES AND RADIOLOGICAL HEALTH | | |
| Device Good Manufacturing Practice Advisory Committee | April 15, October 5–6 | 3014512398 |
| Medical Devices Advisory Committee (Comprised of 18 Panels) | | |

| Committee Name | Tentative Date of Meeting(s) | Advisory Committee 10-Digit Information Line Code |
|---|---|---|
| Anesthesiology and Respiratory Therapy Devices Panel | February 5, April 30, July 23, September 17, November 12 | 3014512624 |
| Circulatory System Devices Panel | February 25, May 27, September 24 | 3014512625 |
| Clinical Chemistry and Clinical Toxicology Devices Panel | March 18–19, June 17–18, October 21–22 | 3014512514 |
| Dental Products Panel | February 11, May 6, June 17, September 16, December 9 | 3014512518 |
| Ear, Nose, and Throat Devices Panel | February 24, May 19, August 18, November 17 | 3014512522 |
| Gastroenterology-Urology Devices Panel | March 20, October 15 | 3014512523 |
| General and Plastic Surgery Devices Panel | February 26–27, June 9–10, October 15–16 | 3014512519 |
| General Hospital and Personal Use Devices Panel | March 25–26, July 29–30, October 21–22 | 3014512520 |
| Hematology and Pathology Devices Panel | April 24, July 17, October 23 | 3014512515 |
| Immunology Devices Panel | October 15–16 | 3014512516 |
| Medical Devices Dispute Resolution Panel | Meetings occur as needed | 3014510232 |
| Microbiology Devices Panel | February 24–25, September 22–23, October 27–28 | 3014512517 |
| Molecular and Clinical Genetics Panel | April 15, October 5–6 | 3014510231 |
| Neurological Devices Panel | February 26–27, May 14–15, September 17–18, December 2–3 | 3014512513 |
| Obstetrics and Gynecology Devices Panel | February 5–6, May 14–15, August 13–14, November 12–13 | 3014512524 |
| Ophthalmic Devices Panel | February 12–13, May 14–15, September 24–25, November 19–20 | 3014512396 |
| Orthopaedic and Rehabilitation Devices Panel | February 3–4, April 14–15, June 9–10, August 11–12, October 15–16, December 1–2 | 3014512521 |
| Radiological Devices Panel | February 18, May 12, August 4, November 17 | 3014512526 |
| National Mammography Quality Assurance Advisory Committee | November 4–5 | 3014512397 |
| Technical Electronic Product Radiation Safety Standards Committee | No meeting tentatively scheduled for 2009 | 3014512399 |
| CENTER FOR FOOD SAFETY AND APPLIED NUTRITION | | |
| Food Advisory Committee | May 20–21 | 3014510564 |
| CENTER FOR VETERINARY MEDICINE | | |
| Veterinary Medicine Advisory Committee | April 14 | 3014512548 |
| NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH (NCTR) | | |
| Science Advisory Board to NCTR | November 17–18 | 3014512559 |

Dated: December 24, 2008.

Randall W. Lutter,

Deputy Commissioner for Policy.

[FR Doc. E9–451 Filed 1–12–09; 8:45 am]

BILLING CODE 4160–01–S

**DEPARTMENT OF HEALTH AND
HUMAN SERVICES**

Food and Drug Administration

[Docket No. FDA–2009–D–0675]

**Draft Guidance for Industry on Good
Importer Practices; Availability**

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing on behalf of several members of the Interagency Working Group on Import Safety (agencies) the availability of a draft guidance for industry entitled “Good Importer Practices.” This draft guidance document provides general recommendations to importers on possible practices and procedures they may follow to increase the likelihood the products they import are in